Larimar Therapeutics, Inc. Income Statement
LRMR|6 years of annual SEC 10-K data (FY2014-FY2019)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Larimar Therapeutics, Inc. reported $0 in revenue and $52M in net loss for FY2019.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| SG&A Expense | $12.2M | $18.3M | $19.2M | $8.1M | $4.2M | $2.2M |
| R&D Expense | $40.8M | $39.9M | $54.6M | $27.4M | $9.6M | $11.5M |
| Operating Income | -$53.0M | -$58.2M | -$73.8M | -$35.5M | -$13.8M | -$13.8M |
| Interest Expense | $165.0K | $529.0K | $806.0K | $870.0K | $870.0K | $97.0K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$52.0M | -$57.9M | -$74.3M | -$36.5M | -$14.0M | -$13.9M |
| EPS (Diluted) | -$1.90 | -$2.12 | -$2.78 | -$3.00 | -$19.53 | -$19.65 |
| Shares Outstanding | 37.3M | 27.5M | 27.3M | 27.2M | 22.9M | 729.4K |